Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment.

NCT06812221 is registered in ClinicalTrials.gov with Biomind Labs Inc. as lead sponsor.

NCT NCT06812221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06812221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment.
Lead sponsor
Biomind Labs Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 15, 2024
Completion date
March 15, 2025
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety state, depression anxiety disorder, mild cognitive impairment